Diabetes and Pregnancy

  Diabetes and Pregnancy: Gestational diabetes Diabetes combined with pregnancy
  Classification
  Pregnancy in Pregnancy Diabetes:Pregnancy in Type 1 and Type 2 Diabetes
  Gestational diabetes mellitus (GDM)
  Gestational hypoglycemia (GIGT): a high risk factor for later conversion to GDM (about 1/3 GIGT)
  Gestational diabetes mellitus
  Higher fasting and postprandial glucose than in normal pregnancy, with increased insulin resistance and decreased insulin sensitivity
  Higher lipid and amino acid concentrations than in normal pregnancy, especially triglyceride levels
  Type 1 diabetes combined with pregnancy
  Hyperglycemia, hyperinsulinism and hyperlipidemia during fasting and postprandial periods due to insulin deficiency or lack of insulin
  Increased rate of hypoglycemia during insulin therapy compared to non-pregnant type 1 diabetic women, which is associated with a further impairment in the ability of pregnant women with type 1 diabetes to counteract and regulate the hypoglycemic response
  Normal metabolic changes in pregnancy have a tendency to cause diabetes
  The combination of diabetes mellitus and pregnancy can lead to further disturbances in the metabolism of various substances, resulting in adverse effects on the mother and child.
  Normalization of metabolic status reduces maternal and child complications
  Study of the mechanism of increased insulin resistance during pregnancy
  As pregnancy increases, the amount of each hormone in the blood of pregnant women: cortisol, progesterone, placental lactogen (or chorionic lactogen, HPL or HCS), pituitary lactogen (PRL) and estrogen, increases gradually and parallels the gradual increase in anti-insulin power; the increase in the amount of these hormones reduces the sensitivity of target cells to insulin.
  Administration of these hormones to non-pregnant women induces metabolic changes similar to those caused by impaired insulin action
  The rate of insulin-mediated glucose uptake is significantly reduced in adipose and skeletal muscle tissue in the above hormonal environment; this reduction is more pronounced in an environment where multiple hormones are combined
  Study on the mechanism of enhanced insulin resistance during pregnancy
  After delivery of the fetus and placenta, the above hormones are no longer secreted, and the insulin resistance phenomenon is rapidly eliminated, leading to maternal and child complications.
  Pregnancy with uncontrolled diabetes can lead to diabetic nephropathy, retinopathy, myocardial infarction, cerebral thrombosis, hypertension, amniotic fluid overload and urinary tract infection.
  The prognosis of pregnant women with diabetes mellitus is related to their diabetes mellitus, and the prognosis is worse as the diabetes mellitus progresses, especially when it is complicated by renal, cardiovascular and other vascular complications.
  Effect of pregnancy on diabetic nephropathy
  Pregnancy can accelerate the deterioration of the disease: increased glomerular filtration rate; increased protein uptake; accelerated development and aggravation of hypertensive complications
  Diabetic nephropathy itself is a progressive disease, and renal function will gradually deteriorate even in the absence of pregnancy
  Although good metabolic control of diabetes can slow the progression of nephropathy, most opinions do not support pregnancy in women with this disease
  Diabetic retinopathy
  Nearly one third of pregnant women with type 1 diabetes have occult or proliferative retinopathy; approximately 4% of non-progressive retinopathy diagnosed at the beginning of pregnancy progresses to the proliferative form
  Risk factors of pregnancy that accelerate the progression of the disease: hypercoagulable state during pregnancy; increased systemic small artery spasm and peripheral vascular resistance due to preeclampsia; increased diabetic microangiopathy; increased placental secretion of various anti-insulin hormones and renin and angiotensin secretion.
  Treatment
  Pregnant women with proliferative retinopathy may have adverse maternal and child outcomes and should not conceive or should terminate their pregnancies.
  Early pregnancy planning can reduce the incidence of this complication; occult lesions are not a contraindication to pregnancy
  Careful ophthalmic examination before pregnancy and fluorescein angiography if necessary, but contraindicated during pregnancy
  If photocoagulation has been performed before pregnancy for proliferative lesions, the rate of vision loss can be reduced by 50% in those affected during pregnancy, and if there is no progression after pregnancy, pregnancy can be carried out or continued
  Perinatal complications
  Perinatal complications are most common in pregnant women with pre-pregnancy diabetes; in addition to congenital malformations, the incidence of perinatal complications is also more common in GDM and GIGT
  The prognosis of the perinatal infant is related to the degree of metabolic control from preconception to pregnancy; moreover, it is related to the complication of vascular disease, which is worse if it has already occurred
  With advances in diabetes treatment and prenatal monitoring, the mortality rate of recent pregnancies and perinatal infants (except for prenatal malformations) has approached that of normal pregnancies; however, perinatal morbidity is still common.
  Perinatal complications
  congenital malformations
  huge babies
  Stillbirth
  increased incidence of neonatal hypoglycemia, hypocalcemia, magnesiumemia, hyperbilirubinemia and erythrocytosis, pulmonary hyaline membrane changes
  Smaller babies, increased incidence of neonatal hypertrophic heart disease, spontaneous abortion and preterm birth, and later obesity, diabetes and impaired intellectual and behavioral development
  Gestational diabetes mellitus (GDM)
  A type of temporary diabetes mellitus that occurs for the first time after pregnancy or is diagnosed with varying degrees of poor carbohydrate tolerance
  GDM occurs in a small number of pregnant women only when the islet ß-cells are severely damaged and there is severe insulin resistance.
  Most GDM is reversible and disappears rapidly after delivery, with the ability to metabolize carbohydrates returning to pre-pregnancy status
  GDM should not be included in cases of pre-pregnancy hypoglycemia that are exposed only after pregnancy, but it is extremely difficult to identify them.
  Those who fail to return to normal one year after delivery should be reclassified
  High risk factors for GDM
  Family history of diabetes, especially first-degree relatives, mainly the mother
  Gestational age 30 years
  Obesity: actual weight above 120% of standard weight or BMI ≥ 27 kg/m2
  History of unexplained recurrent miscarriage, stillbirth, or stillbirth
  excessive amniotic fluid and large fetus in the current pregnancy
  Symptoms of polyhydramnios, polyuria and polyphagia
  Skin infection and mycosis vaginalis with recurrent episodes
  Positive fasting morning urine glucose, especially if detected at 24-28 weeks of gestation
  Screening for GDM Most people prefer universal screening
  Screening period: 24-28 weeks of gestation for primary screening, 32-34 weeks of gestation for repeat screening
  Judgment criteria: 1 hour after fasting oral glucose 50g, blood glucose value <7.2 (130mg/dl) can exclude GDM; 7.2mmol/L, then need to do 75g or 100g glucose 3 hours OGTT; for emergency cases, can be done at any time
  GDM diagnosis
  GDM screening measures (GCT) to identify the presence or absence of postprandial hyperglycemia ability is lower than OGTT. Because the relatively short cycle of 50g glucose load is difficult to reflect the changes in islet function after provocation
  75g and 100g glucose 3-hour OGTT have similar rates of correctly diagnosing GDM, and both can be used as a basis for diagnosis
  The OGTT should be preceded by an overnight fast of 8-14 hours, with no restriction on diet or exercise for the previous 3 days, sitting still, not smoking, and drinking water during the test
  OGTT diagnostic criteria for GDM
  Treatment of gestational diabetes
  The aim of treatment is to ensure maternal health and normal fetal development
  Blood sugar should be maintained at normal level, fasting blood sugar
  ≤5.8 mmol/L
  2 hours postprandial blood glucose ≤6.7mmol/L, HbA1c<6%;
  Each region should set its own normal level of OGTT
  During treatment, hypoglycemia and ketosis should be avoided
  Nutritional treatment (I)
  In order to supply pregnant women and fetuses with adequate nutrition, it is necessary to reasonably
  control the total calories.
  The whole pregnancy is divided into three periods, the first period is from 1 to 3 months, and the second period is from 4 to 4 months.
  The first period is from 1 to 3 months, the second period is from 4 to 6 months, and the third period is from 7 to 9 months.
  The calorie intake in the first period is the same as before pregnancy. Starting from the second trimester
  The calorie intake should be 38 Kcal/kg/day according to the pre-pregnancy ideal weight.
  Even if gestational diabetes occurs in obese women, it is not considered
  Weight loss during pregnancy. Weight gain during pregnancy should not
  The weight gain during pregnancy should not exceed 12 kg.
  Nutritional treatment (II)
  Carbohydrate intake should be 200-300g/day, too little carbohydrate is prone to ketosis.
  Increase the protein intake by 15-25g/day (including at least 1/3 of high quality protein).
  Pregnant women should be encouraged to eat more fresh green vegetables for vitamin supplementation and pig liver and pig blood products for iron supplementation, as well as iodine-containing foods.
  Total calories should be divided into five to six meals throughout the day, and small and frequent meals will help to control blood sugar steadily and reduce the chance of postprandial hyperglycemia and preprandial hypoglycemia.
  Exercise therapy
  Moderate exercise, suitable for pregnant women with GDM and type 2 diabetes
  Emphasize the safety of exercise
  Attention to individualization
  Insulin therapy
  When pregnant women’s blood glucose cannot be maintained in the normal range
  Insulin therapy should be given
  The insulin preparation should be genetically recombinant human insulin.
  Short-acting human insulin should be injected three to four times a day. If necessary
  If necessary, medium-acting insulin should be added once before bedtime to control the morning hyperglycemia.
  Morning hyperglycemia
  Oral hypoglycemic drugs should not be used
  The principles of insulin therapy for GDM are different from those for non-pregnant diabetes
  Postprandial hyperglycemia is much more common in GDM than in FPG, so it is advisable to treat with a combination of medium and short-acting agents.
  Before 30 weeks of pregnancy, the metabolism is still unstable, insulin secretion and sensitivity to insulin are decreased, so the insulin requirement increases, and frequent blood glucose measurement is necessary to correct the dose; after 30 weeks of pregnancy, the glucose metabolism becomes stable, and the insulin requirement is relatively consistent.
  Stop using medium-acting insulin preparations 3-7 days after delivery
  After delivery, insulin dosage should be reduced to no use
  Long-acting insulin should not be used during pregnancy
  Blood glucose monitoring
  Since the renal glucose threshold is lower in women during pregnancy, even
  urine glucose can be positive even in the presence of normal blood glucose.
  Therefore, urine glucose test cannot be used as an observation indicator, but should be tested
  Blood glucose should be tested to understand the condition and adjust the treatment in time.
  Blood glucose test can be checked at the hospital, or the patient can use the blood glucose meter to check and record by himself.
  Monitoring the blood glucose value one hour after meal is better than before meal
  Outpatient follow-up
  Pregnant women with gestational diabetes must visit the obstetrics clinic regularly for checkups.
  This includes checking for gestational hypertension and ultrasound in the third trimester.
  Fetal size to determine the need to prepare for cesarean delivery
  Pregnant women with gestational diabetes must also visit the diabetes clinic every one to two weeks to check their blood glucose and adjust their insulin levels.
  The glucose should be checked at the diabetes clinic every 1 to 2 weeks, the insulin dose should be adjusted, and dietary guidance should be given.
  Postpartum observation
  The majority of gestational diabetes can stop insulin after delivery, only a few patients still need a small amount of insulin.
  A 75g glucose tolerance test is performed 6 to 8 weeks after delivery to clarify the diagnosis of diabetes.
  About 2% have type 2 diabetes, 8% have low glucose tolerance, and 60-70% have normal glucose tolerance.
  More type 2 diabetes will be found after long-term observation
  The Department of Endocrinology of Peking Union Medical College Hospital has followed up 30 cases of gestational diabetes for 20 years.
  Among them, 25 cases had type 2 diabetes, 3 cases had normal OGTT and 2 cases were lost to follow-up.
  Appropriate postpartum diet control and avoidance of obesity are the basic measures to prevent or delay the onset of type 2 diabetes mellitus.
  Postpartum education of GDM
  Explain the importance of maintaining proper weight and measuring OGTT once a year
  Seek medical attention in case of hyperglycemia
  Maintain the diet plan implemented in late pregnancy to meet the needs of breastfeeding
  Encourage breastfeeding
  Low-dose oral contraceptives are safe and effective for people with a history of GDM
  Use adverse glucose metabolism medications with caution
  Pre-conception planning for women with diabetes
  Comprehensive assessment for vascular complications
  Switch from oral hypoglycemic agents to insulin therapy
  Adjustment of diet control
  Knowledge and practice of self-monitoring and management of diabetes mellitus
  Terminate contraception if well controlled and take BBT to determine conception date
  Stop taking contraceptive pills 3 months before planned conception and replace them with instrumental contraception
  Avoid ultrasound in early pregnancy without special indications
  Fertility and spontaneous abortion
  Normal fertility in diabetic women with well-controlled metabolism and no complications
  The rate of spontaneous abortion in diabetic pregnant women with well-controlled blood glucose is similar to that of non-diabetic pregnant women
  The rate of spontaneous abortion is significantly higher in early pregnancy when HbA1c levels are significantly elevated
  Genetic predisposition to diabetes
  Parents with type 1 diabetes have a 2% to 6% chance of passing the disease on to their offspring.
  The incidence of diabetes in the offspring of pregnant women with type 2 diabetes is unclear and is associated with race, obesity, etc.
  Pregnancy is not prohibited in women with diabetes
  Congenital malformations
  Good glycemic control before pregnancy and during early pregnancy can significantly reduce the rate of congenital malformations; however, it cannot absolutely guarantee the birth of a completely healthy child.
  If the blood glucose control is poor, such as HbA1C is significantly increased in early pregnancy, the rate of congenital malformation is 10-25%.
  For suspected congenital malformations, blood and amniotic fluid AFP and amniotic fluid AChE analysis should be performed to determine whether there are congenital open defects.
  Ultrasound and color ultrasound can detect bone, central nervous system, cardiovascular and renal malformations; there is no measure for 100% diagnostic compliance
  The participation of every diabetic woman of childbearing age in counseling, training and guidance before and throughout pregnancy is an important measure to reduce the rate of maternal and child complications in the near and long term after pregnancy
  The importance of joint multidisciplinary guidance, education, awareness and training
  The importance of mobilizing patients to actively participate and cooperate in various treatment plans before and after pregnancy, labor and delivery, postpartum, and long-term follow-up